Live sessions will be recorded and available for On-Demand viewing from September 20, 2021.
| Program DAY 1 | Date/Time (JST) |
Date/Time (PDT) |
Date/Time (EDT) |
|
|---|---|---|---|---|
|
Keynote Session Chair: Dr. Hiroyuki Mano(National Cancer Center, Tokyo, Japan) (JCA) Chair: Dr. Elaine R. Mardis (Nationwide Children’s Hospital, Columbus, Ohio, USA) (AACR) |
9/11 Sat. 8:00-8:55 |
9/10 Fri. 16:00-16:55 |
9/10 Fri. 19:00-19:55 |
|
|
KS-1: National Platform for Cancer Precision Medicine in Japan Dr. Hiroyuki Mano(National Cancer Center, Tokyo, Japan) (JCA) |
||||
|
KS-2: Genomics-Guided Pediatric Cancer Precision Medicine: New Developments Dr. Elaine R. Mardis(Nationwide Children’s Hospital, Columbus, Ohio, USA) (AACR) |
||||
|
Plenary 1: (National Cancer Center Hospital East, Chiba, Japan) Chair: Dr. Lillian L. Siu (UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada) |
9/11 Sat. 9:00-10:45 |
9/10 Fri. 17:00-18:45 |
9/10 Fri. 20:00-21:45 |
|
|
PL1-1: Circulating DNA for Liquid Biopsies: Coming in Different Sizes and Shapes Dr. Dennis Lo(Chinese University of Hong Kong, Hong Kong, China-Hong Kong) |
||||
|
PL1-2: Exosomal PD-L1: Role in Immune Suppression and Potential Application in Immune Oncology Dr. Wei Guo(University of Pennsylvania, Philadelphia, Pennsylvania, USA) |
||||
|
PL1-3: Liquid Biopsy to Enable MRD Detection and Interception and the Precise Use of Immunotherapy Dr. Lillian L. Siu(UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada) |
||||
|
PL1-4: Near Future Forecast of Precision Oncology using Liquid Biopsy Technology Dr. Takayuki Yoshino(National Cancer Center Hospital East, Chiba, Japan) |
||||
| Break | ||||
|
Program 1: (Dana-Farber Cancer Institute, Boston, Massachusetts, USA) Chair: Dr. Seishi Ogawa (Kyoto University, Kyoto, Japan) |
Program 2: (OHSU Knight Cancer Institute, Portland, Oregon, USA) Chair: Dr. Shinichi Yachida (Osaka University, Osaka, Japan) |
9/11 Sat. 11:00-12:30 |
9/10 Fri. 19:00-20:30 |
9/10 Fri. 22:00-23:30 |
|
PG01-1: Clonal Hematopoiesis and the Origins of Blood Cancers Dr. Benjamin L. Ebert(Dana-Farber Cancer Institute, Boston, Massachusetts, USA) |
PG02-1: Spatial Immunoprofiling for Stratification of Cancer Patients for Immunotherapy Dr. Shohei Koyama(National Cancer Center, Tokyo) |
|||
|
PG01-2: Clonal Expansion in Apparently Normal Tissues Dr. Seishi Ogawa(Kyoto University, Kyoto, Japan) |
PG02-2: Functional Genomics for Therapeutic Innovation in Hematologic Malignancies Dr. Jeffrey W. Tyner(OHSU Knight Cancer Institute, Portland, Oregon, USA) |
|||
|
PG01-3: Somatic Mutations in Normal Bronchial Epithelia Dr. Kenichi Yoshida(Wellcome Sanger Institute, Saffron Walden, United Kingdom) |
PG02-3: Human Fecal Microbiome-Based Biomarkers for Colorectal Cancer (Live only) Dr. Shinichi Yachida(Osaka University, Osaka, Japan) |
|||
| Break | ||||
|
SS-1A: Leading with Data: Tumor-informed ctDNA Testing across Cancer Types (Aichi Cancer Center) Speaker: Dr. Angel Rodriguez (Natera) |
SS-1B: Genomes for Precision Oncology (National Cancer Center, Tokyo) Speaker: Dr. David Bentley (Illumina, Inc.) |
9/11 Sat. 12:40-13:10 |
9/10 Fri. 20:40-21:10 |
9/10 Fri. 23:40-1:10(9/11) |
|
SS-2A: A New Therapeutic Cancer Vaccine inducing Multifunctional Immunity, Artificial Adjuvant Vector Cells (Faculty of Medicine, Kagawa University) Speaker: Dr. Shin-ichiro Fujii (Team Leader, Laboratory for Immunotherapy, Center for Integrative Medical Sciences, RIKEN Vice Director, Program for Drug Discovery and Medical Technology Platforms, RIKEN) |
SS-2B: Comprehensive Cancer Gene Profiling for Precision Oncology (National Cancer Center, Tokyo) Speaker: Dr. Hiroyuki Aburatani (Research Center for Advanced Science and Technology, The University of Tokyo) |
9/11 Sat. 13:15-13:45 |
9/10 Fri. 21:15-21:45 |
9/11 Sat. 1:15-1:45 |
|
SS-3A: Leading the Way in Target Enrichment: Exceptional Performance, Improved Efficiency and Rapid Customization of Targeted Methylation Sequencing (Senior Sales Director, Asia Pacific, Twist Bioscience) Speaker: Mr. Bryan Hoglund (Senior Manager, NGS Business Solutions, Twist Bioscience) |
SS-3B: Considerations for Incorporating Biomarkers into Real World Dataset (National Cancer Center, Tokyo) Speaker: Dr. Anna Berry (Syapse) |
9/11 Sat. 13:50-14:20 |
9/10 Fri. 21:50-22:20 |
9/11 Sat. 1:50-2:20 |
| Break | ||||
Program 3: (The Cancer Chemotherapy Center, JFCR, Tokyo, Japan) |
Program 4: (Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo Director, Department of Clinical Genomics The University of Tokyo Hospital, Japan) |
9/11 Sat. 14:30-16:00 |
9/10 Fri. 22:30-0:00(9/11) |
9/11 Sat. 1:30-3:00 |
|
PG03-1: HDAC3 is a Targetable Mediator of Therapeutic Resistance in Non-small Cell Lung Cancer Dr. Reuben J. Shaw(Salk Institute, La Jolla, California, USA) |
PG04-1: Large-scale Germline Sequencing of Hereditary Cancer Genes in >60,000 Cancer Patients and Controls Dr. Yukihide Momozawa(RIKEN Center for Integrative Medical Sciences Laboratory for Genotyping Development, Kanagawa, Japan) |
|||
|
PG03-2: Mechanisms of Intrinsic Resistance Mediated by Tumor (The Cancer Chemotherapy Center, JFCR, Tokyo, Japan) |
PG04-2: High Throughput Functional Analysis for the Clinical Annotation in Cancer Genome Medicine Dr. Shinji Kohsaka(National Cancer Center, Tokyo) |
|||
|
PG03-3: RAS Proteins in Human Disease Dr. Frank McCormick(UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA) |
PG04-3: Germline Predispositions to Hematologic Malignancies Dr. Courtney D. DiNardo(UT MD Anderson Cancer Center, Houston, Texas, USA) |
|||
| ePoster presentation is available all the time during the conference as well as On-demand distribution by December 31 | ||||
| Program DAY 2 | Date/Time (JST) |
Date/Time (PDT) |
Date/Time (EDT) |
|
|---|---|---|---|---|
Plenary 2: (National Cancer Center, Tokyo) Chair: Dr. Elizabeth M. Jaffee (Johns Hopkins University, Baltimore, Maryland, USA) |
9/12 Sun. 8:00-9:45 |
9/11 Sat. 16:00-17:45 |
9/11 Sat. 19:00-20:45 |
|
|
PL2-1: Integrity of the IFN and MHC Signaling Pathways in Tumor Immunity and Therapy Dr. Weiping Zou(University of Michigan, Ann Arbor, Michigan, USA) |
||||
|
PL2-2: Immunosuppression by Regulatory T Cells in the Tumor Microenvironment Dr. Hiroyoshi Nishikawa(National Cancer Center, Tokyo) |
||||
|
PL2-3: Pancreatic Cancer Treatment in the Era of Precision Immunotherapy Dr. Elizabeth M. Jaffee(Johns Hopkins University, Baltimore, Maryland, USA) |
||||
|
PL2-4: Epigenetic Insights into T Cell Longevity for Optimal Adoptive Immunotherapy Dr. Yuki Kagoya(Aichi Cancer Center Research Institute, Nagoya, Japan) |
||||
| Break | ||||
Program 5: (Keio University School of Medicine, Tokyo, Japan) Chair: Dr. Elli Papaemmanuil (Memorial Sloan Kettering Cancer Center, New York, New York, USA) |
Program 6: (Cancer Science Institute of Singapore, NUS, Singapore, Singapore) Chair: Dr. Nilofer S. Azad (Johns Hopkins University, Baltimore, Maryland, USA) |
9/12 Sun. 10:00-11:30 |
9/11 Sat. 18:00-19:30 |
9/11 Sat. 21:00-22:30 |
|
PG05-1: Multicellular Ecosystem in HTLV-1 Viral Carcinogenesis Revealed by Multi-omics Single-cell Analysis Dr. Keisuke Kataoka(Keio University School of Medicine, Tokyo, Japan) |
PG06-1: Recent Advances in the (Epi)genomic Landscape of Gastric Cancer Dr. Patrick Tan(Cancer Science Institute of Singapore, NUS, Singapore, Singapore) |
|||
|
PG05-2: Population Genomic Studies to Advance Precision Medicine Practices in Myeloid Neoplasms Dr. Elli Papaemmanuil(Memorial Sloan Kettering Cancer Center, New York, New York, USA) |
PG06-2: Trans-ethnic Driver Landscape of Gastric Cancer Dr. Tatsuhiro Shibata(The Institute of Medical Science, The University of Tokyo, Tokyo, Japan) |
|||
|
PG05-3: Understanding and Targeting Aberrant Splicing in Leukemias Dr. Akihide Yoshimi(Cancer RNA Research Unit, National Cancer Center Research Institute, Tokyo, Japan) |
PG06-3: The Emerging Understanding of Phenotypes of Biliary Tract Cancers Dr. Nilofer S. Azad(Johns Hopkins University, Baltimore, Maryland, USA) |
|||
| Break | ||||
|
SS-4A: WGS and WES with DNBSEQ Technology for Precision Oncology (National Cancer Center, Tokyo) Speaker: Mr. Toby Huang (BD Director at MGI) Speaker: Prof. Steven Jones (University of British Columbia) |
SS-4B: Fecal Microbiome Profiling in the SCRUM-Japan MONSTAR-SCREEN Project Reveals Novel Connections between Tumor and Gut Microbiota (CBO (Chief Business Officer), bitBiome, Inc.) Speaker: Dr. Riu Yamashita (Translational Informatics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center) |
9/12 Sun. 11:40-12:10 |
9/11 Sat. 19:40-20:10 |
9/11 Sat. 22:40-23:10 |
|
SS-5A: Real World Data Insights for the Advancement of Precision Medicine (Department of Gastrointestinal Oncology, National Cancer Center Hospital East) Speaker: Dr. Ivy Altomare (Medical Director, Flatiron Health Inc.) |
SS-5B: Precision Medicine in Cancer (National Cancer Center, Tokyo) Speaker: Prof. Raju Kucherlapati (Harvard Medical School) |
9/12 Sun. 12:15-12:45 |
9/11 Sat. 20:15-20:45 |
9/11 Sat. 23:15-23:45 |
|
SS-6A: Web-based Treatment Decision Support Tool for Precision Medicine (Kyoto University, Graduate School of Medicine) Speaker: Prof. Masashi Kanai (Kyoto University, Graduate School of Medicine) |
9/12 Sun. 12:50-13:20 |
9/11 Sat. 20:50-21:20 |
9/11 Sat. 23:50-0:20(9/12) |
|
| Break | ||||
Program 7: (National Cancer Center, Tokyo) Chair: Dr. Calvin J. Kuo (Stanford University, Stanford, California, USA) |
Program 8: (National Cancer Center, Tokyo) |
9/12 Sun. 13:30-15:00 |
9/11 Sat. 21:30-23:00 |
9/12 Sun. 0:30-2:00 |
|
PG07-1: Modeling Tumor Tissue Complexity with 3D Bioprinting Dr. Rosalie C. Sears(Oregon Health & Science University, Portland, Oregon, USA) |
PG08-1: Utilization of Large Scale Real-world Tumor Profiling Data Obtained from Daily Cancer Treatment Dr. Takashi Kohno(National Cancer Center, Tokyo) |
|||
|
PG07-2: Organoid Modeling of Tumor Genomes and Microenvironments (Live only) Dr. Calvin J. Kuo(Stanford University, Stanford, California, USA) |
PG08-2: Real-World Evidence in K-MASTER Cancer Precision Medicine Program Dr. Yeul Hong Kim(Korea University, Seoul, Korea) |
|||
|
PG07-3: Drug Discovery and Development Research for New Anticancer Agents based on Pharmacokinetic and Pharmacodynamic Analysis using Patient-derived Xenograft (J-PDX) Library Dr. Akinobu Hamada(National Cancer Center, Tokyo) |
PG08-3: AACR Project GENIE: Powering Precision Medicine through International Data-Sharing Dr. Philippe L. Bedard(UHN Princess Margaret Cancer Centre, USA) |
|||
| Break | ||||
Program 9: (The University of Tokyo, Tokyo, Japan) Chair: Dr. Trey Ideker (UC San Diego, La Jolla, California, USA) |
Program 10: (Kyoto University, Kyoto, Japan) Chair: Dr. Michelle Haber (Children's Cancer Institute, Sydney, Australia) |
9/12 Sun. 15:15-16:45 |
9/11 Sat. 23:15-0:45(9/12) |
9/12 Sun. 2:15 -3:45 |
|
PG09-1: Building the Mind of Cancer Dr. Trey Ideker(UC San Diego, La Jolla, California, USA) |
PG10-1: Integrated Genetic and Epigenetic Analysis of Pediatric Cancers Dr. Junko Takita(Kyoto University, Kyoto, Japan) |
|||
|
PG09-2: Universal Encoding of Cancer Histology by Deep Neural Network Dr. Shunpei Ishikawa(The University of Tokyo, Tokyo, Japan) |
PG10-2: Zero Childhood Cancer: A Whole of System National Approach to Improving Outcomes of Australian Children with Cancer through Precision Medicine Dr. Michelle Haber(Children's Cancer Institute, Sydney, Australia) |
|||
|
PG09-3: Convergence of Machine Learning and Genomics for Precision Cancer Medicine Dr. Eliezer Van Allen(Dana-Farber Cancer Institute, Boston, Massachusetts, USA) |
PG10-3: Genomic Variants in Pediatric Cancer: Model for Relapse, Precision Medicine, and Data Sharing Ecosystem Dr. Jinghui Zhang(St. Jude Children's Research Hospital, Memphis, Tennessee, USA) |
|||
| ePoster presentation is available all the time during the conference as well as On-demand distribution by December 31 | ||||
Liquid Biopsy
Immuno-oncology
Hematology
Pediatric Cancer
Drug Resistance
Germline Predisposition
Novel Platforms for Precision Medicine
Research Focused on Asian Cancers
Real-World Evidence in Precision Medicine
Somatic Mutations in Precancerous Tissue
Cancer Model Systems
AI in Precision Medicine